NCT04191213 (GA&SCA) is a Phase 2, PHASE3 clinical trial of Acacia Senegal extract in Sickle Cell Anemia in Children, sponsored by Al-Neelain University.

Who is sponsoring NCT04191213?

NCT04191213 is sponsored by Al-Neelain University.

What drugs are being tested in NCT04191213?

Interventions in NCT04191213: Acacia Senegal extract, Pectin.

What condition does NCT04191213 study?

NCT04191213 studies Sickle Cell Anemia in Children.

Is NCT04191213 still recruiting?

NCT04191213 is currently status unknown. Last updated 28 January 2020.

Last reviewed 2020-01-28 · How we verify

NCT04191213: GA&SCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gum Arabic as Anti-oxidant, Anti-inflammatory and Fetal Hemoglobin Inducing Agent in Sickle Cell Anemia Patients

Status unknown Phase 2, PHASE3 Last updated 28 January 2020

What this trial tests

Phase 2, PHASE3 trial testing Acacia Senegal extract in Sickle Cell Anemia in Children in 100 participants. Status unknown.

Timeline

15 February 2020

Primary endpoint
15 June 2020

15 July 2020

Quick facts

Lead sponsor	Al-Neelain University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	100
Start date	15 February 2020
Primary completion	15 June 2020
Estimated completion	15 July 2020
Sites	1 location across Sudan

Drugs / interventions tested

Acacia Senegal extract
Pectin (PECTIN) — full drug profile →

Conditions studied

Sickle Cell Anemia in Children — all drugs for Sickle Cell Anemia in Children →

Sponsor

Al-Neelain University

Who can join

Adults 3 to 18, any sex, with Sickle Cell Anemia in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To study the efficacy of Gum Arabic as an anti-oxidant, anti-inflammatory and Fetal Hemoglobin-inducing agent among Sickle Cell Disease children. Half of participants will receive Gum Arabic and the other half will receive placebo

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Acacia Senegal extract

Trials testing the same drug.

NCT04215380 — Effects of Gum Arabic Ingestion on Hormonal and Metabolic Changes in Patients With Polycystic Ovary Syndrome · NA · unknown

Other recruiting trials for Sickle Cell Anemia in Children

Currently open trials in the same condition.

NCT05285917 — Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa · Phase 3 · recruiting
NCT06387758 — Low Systemic/High Local Exercise Load in Peds SCD · NA · recruiting

Other Al-Neelain University trials

Trials by the same sponsor.

NCT04381871 — Potential Role of Gum Arabic as Immunomodulatory Agent Among COVID 19 Patients · Phase 2, PHASE3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04191213 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Al-Neelain University
Last refreshed: 28 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04191213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing